Anika Therapeutics Inc (ANIK) 41.10 $ANIK
Nasdaq stocks posting largest percentage decreases
AP - Thu Jul 31, 5:04PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at the close of trading:
Major Indexes Extend Losses; S&P 500 Breaks 50-Day Line
at Investor's Business Daily - Thu Jul 31, 10:50AM CDT
Stocks lost more ground near the midpoint of Thursday's session. They had been under pressure from the start amid Argentina's debt default and mixed economic data. The Nasdaq slumped 1.6%, hurt by software and chip stocks. The S&P 500 dropped 1.3%,...
Anika Therapeutics partners with Medline for marketing of wound care product Hyalomatrix
M2 - Thu Jul 31, 6:15AM CDT
Therapeutic products company Anika Therapeutics (NasdaqGS:ANIK) reported on Wednesday the execution of an exclusive agreement to commercialise its Hyalomatrix in the US in partnership with Medline Industries
ANIKA THERAPEUTICS
at Investor's Business Daily - Wed Jul 30, 6:03PM CDT
ANIKA THERAPEUTICS (ANIK), a bone-healing product maker, said Q2 EPS rose 50% to 60 cents, beating by 3 cents. Sales increased 26% to $26.3 mil, but missed views for $28.2 mil. Shares fell 6.5% to 46.50.
Anika Therapeutics Reports Second-Quarter 2014 Financial Results
Business Wire - Wed Jul 30, 3:05PM CDT
--Commercial Launch of Monovisc(R) Generates $5 Million Milestone Payment
Anika Therapeutics Announces U.S. Commercialization Partnership for Hyalomatrix(R) with Wound Care Leader Medline Industries, Inc.
Business Wire - Wed Jul 30, 12:04PM CDT
Anika Therapeutics, Inc. (Nasdaq: ANIK) today announced that it has entered into a new agreement with Medline Industries, Inc. to commercialize the Company's advanced wound care product - Hyalomatrix(R), in the United States on an exclusive basis through 2019. According to the agreement, Anika will receive product payment and royalty revenues from the sale of the product by Medline. Hyalomatrix(R) is a biologically-derived matrix for in-growing cells, and has the U.S. Food and Drug Administration marketing clearance.
Anika Therapeutics Up 36.4% Since SmarTrend Uptrend Call (ANIK)
Comtex SmarTrend(R) - Mon Jul 28, 5:06PM CDT
SmarTrend identified an Uptrend for Anika Therapeutics (NASDAQ:ANIK) on February 21st, 2014 at $34.67. In approximately 5 months, Anika Therapeutics has returned 36.35% as of today's recent price of $47.28.
Scheduled Conference Calls and Product Launches - Research Reports on Anika Therapeutics, NeoGenomics, HeartWare, Sangamo and Dyax
PR Newswire - Wed Jul 23, 7:40AM CDT
Today, Analysts Review released its research reports regarding Anika Therapeutics, Inc. (NASDAQ: ANIK), NeoGenomics, Inc. (NASDAQ: NEO), HeartWare International Inc (NASDAQ: TWR), Sangamo BioSciences, Inc. (NASDAQ: SGMO) and Dyax Corp (NASDAQ: DYAX). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/5011-100free.
Global Hyaluronic Acid Products (Single-Injection, Three-Injection Cycle and Five-Injection Cycle) Market 2014-2019
M2 - Mon Jul 21, 3:50AM CDT
Research and Markets (http://www.researchandmarkets.com/research/6ct2qw/hyaluronic_acid) has announced the addition of the "Global Hyaluronic Acid Products (Single-Injection, Three-Injection Cycle and Five-Injection Cycle) Market 2014-2019" report to their offering. Hyaluronic acid (HA) is a glycosaminoglycan that helps in transportation of nutrients through the body and facilitate water retention in body tissue. It is naturally found in body - in joints, eye cavity, immune system and others. HA was observed to be an important component of articular cartilage where it is present in the form of a coat around each chondrocyte. This report studies the global hyaluronic acid products market by types of products, applications and the major geographic markets. Products market is segmented as single-injection, three-injection cycle and five-injection cycle. Similarly, applications market is segmented as osteoarthritis, ophthalmic surgery, dermal fillers and vesicoureteral reflux (VUR). The market overview section of the hyaluronic acid products market report discusses the market dynamics with respect to market drivers, restraints and opportunities. This section also covers market attractiveness analysis (by geography) and Porter's five forces analysis for the global hyaluronic acid products market. Market share (%) for the major players operating in this market has also been provided for the year 2012, followed by a list of recommendations for the existing and new players to enter and enhance their market shares. The report concludes with the company profiles of key players operating in various segments of the market. Each company profile includes the business overview, financial overview, product portfolio, business strategies and recent developments of the respective company. Some of the prominent players in the hyaluronic acid products market that have been profiled in this report include Allegran Inc., Anika Therapeutics, Inc., Merz Aesthetics, Inc., Sanofi (Genzyme) and Seikagaku. The global hyaluronic acid products market is segmented as follows: Hyaluronic Acid Products Market, by Products - Single-injection - Three-injection cycle - Five-injection cycle Hyaluronic Acid Products Market, by Applications - Osteoarthritis - Ophthalmic - Dermal Fillers - Vesicoureteral Reflux (VUR) Key Topics Covered: Chapter 1 Introduction Chapter 2 Executive Summary Chapter 3 Market Overview Chapter 4 Global Hyaluronic Acid Products Market, by Products Chapter 5 Global Hyaluronic Acid Products Market, by Applications Chapter 6 Global Hyaluronic Acid Products Market, by Geography Chapter 7 Recommendations Chapter 8 Company Profiles - Alcon, Inc. - Allergan, Inc. - Anika Therapeutics, Inc. - F. Hoffmann-La Roche Ltd. - Ferring Pharmaceuticals, Inc. - Fidia Farmaceutici SpA - GALDERMA S.A. - Hyaltech Ltd. - LifeCore Biomedical LLC, - Meiji Seika Pharma Co., Ltd. - Merz Aesthetics, Inc. - Sanofi - Salix Pharmaceuticals, Inc. - Seikagaku Corporation - Shanghai Jingfeng Pharmaceutical Co., Ltd. - Smith & Nephew plc - TRB CHEMEDICA INTERNATIONAL SA - Zimmer Holdings, Inc. For more information visit http://www.researchandmarkets.com/research/6c...ronic_acid
Anika Therapeutics Announces Date of Second-Quarter 2014 Financial Results Conference Call
Business Wire - Tue Jul 15, 3:05PM CDT
Anika Therapeutics, Inc. (Nasdaq: ANIK) today announced that it plans to issue its second-quarter 2014 financial results after the close of the market on Wednesday, July 30, 2014. The company plans to hold a conference call the next day, Thursday, July 31 at 9:00 a.m. ET to discuss its financial results, business highlights and outlook. In addition, the company will answer questions concerning business and financial developments and trends, and other business and financial matters affecting the company, some of the responses to which may contain information that has not been previously disclosed.
44.4% Return Seen to Date on SmarTrend Anika Therapeutics Call (ANIK)
Comtex SmarTrend(R) - Mon Jul 14, 9:40AM CDT
SmarTrend identified an Uptrend for Anika Therapeutics (NASDAQ:ANIK) on February 21st, 2014 at $34.68. In approximately 5 months, Anika Therapeutics has returned 44.37% as of today's recent price of $50.06.
Biotech Stocks Gilead, Anika Still Near Buy Points
at Investor's Business Daily - Mon Jul 07, 4:39PM CDT
Biotechs Gilead Sciences (GILD) and Anika Therapeutics (ANIK) are among just a few stocks in the Spotlight screen that are still hovering near buy points. Anika, which makes treatments for tissue protection, healing and repair, cleared a 49.47 buy...
Uptrend Call Working As Anika Therapeutics Stock Rises 41.6% (ANIK)
Comtex SmarTrend(R) - Mon Jul 07, 9:20AM CDT
SmarTrend identified an Uptrend for Anika Therapeutics (NASDAQ:ANIK) on February 21st, 2014 at $34.68. In approximately 5 months, Anika Therapeutics has returned 41.60% as of today's recent price of $49.10.
Appointments, Acquisitions, Study Results, and Technical Updates - Analyst Notes on Alere, AMRI, Anika Therapeutics, Nektar and Sangamo
PR Newswire - Fri Jul 04, 5:30AM CDT
Today, Analysts Review released its analysts' notes regarding Alere Inc. (NYSE: ALR), Albany Molecular Research Inc. (NASDAQ: AMRI), Anika Therapeutics Inc. (NASDAQ: ANIK), Nektar Therapeutics (NASDAQ: NKTR) and Sangamo Biosciences Inc. (NASDAQ: SGMO). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/4465-100free.
35.5% Return Seen to Date on SmarTrend Anika Therapeutics Call (ANIK)
Comtex SmarTrend(R) - Fri Jun 27, 9:12AM CDT
SmarTrend identified an Uptrend for Anika Therapeutics (NASDAQ:ANIK) on February 21st, 2014 at $34.68. In approximately 4 months, Anika Therapeutics has returned 35.54% as of today's recent price of $47.00.
Anika Therapeutics Has Returned 31.8% Since SmarTrend Recommendation (ANIK)
Comtex SmarTrend(R) - Thu Jun 19, 4:50PM CDT
SmarTrend identified an Uptrend for Anika Therapeutics (NASDAQ:ANIK) on February 21st, 2014 at $34.68. In approximately 4 months, Anika Therapeutics has returned 31.77% as of today's recent price of $45.69.
Pricing of Offering, FDA Approvals, Launches, and Technical Updates - Analyst Notes on Tenet, Lannett, Wright Medical Group, Anika Therapeutics and Accuray
PR Newswire - Thu Jun 19, 5:00AM CDT
Today, Analysts Review released its analysts' notes regarding Tenet Healthcare Corp. (NYSE: THC), Lannett Company, Inc. (NYSE: LCI), Wright Medical Group Inc. (NASDAQ: WMGI), Anika Therapeutics Inc. (NASDAQ: ANIK) and Accuray Incorporated (NASDAQ: ARAY). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/3879-100free.
Nasdaq stocks posting largest percentage decreases
AP - Thu Jul 31, 5:04PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at the close of trading:
Major Indexes Extend Losses; S&P 500 Breaks 50-Day Line
at Investor's Business Daily - Thu Jul 31, 10:50AM CDT
Stocks lost more ground near the midpoint of Thursday's session. They had been under pressure from the start amid Argentina's debt default and mixed economic data. The Nasdaq slumped 1.6%, hurt by software and chip stocks. The S&P 500 dropped 1.3%,...
Anika Therapeutics partners with Medline for marketing of wound care product Hyalomatrix
M2 - Thu Jul 31, 6:15AM CDT
Therapeutic products company Anika Therapeutics (NasdaqGS:ANIK) reported on Wednesday the execution of an exclusive agreement to commercialise its Hyalomatrix in the US in partnership with Medline Industries
ANIKA THERAPEUTICS
at Investor's Business Daily - Wed Jul 30, 6:03PM CDT
ANIKA THERAPEUTICS (ANIK), a bone-healing product maker, said Q2 EPS rose 50% to 60 cents, beating by 3 cents. Sales increased 26% to $26.3 mil, but missed views for $28.2 mil. Shares fell 6.5% to 46.50.
Anika Therapeutics Reports Second-Quarter 2014 Financial Results
Business Wire - Wed Jul 30, 3:05PM CDT
--Commercial Launch of Monovisc(R) Generates $5 Million Milestone Payment
Anika Therapeutics Announces U.S. Commercialization Partnership for Hyalomatrix(R) with Wound Care Leader Medline Industries, Inc.
Business Wire - Wed Jul 30, 12:04PM CDT
Anika Therapeutics, Inc. (Nasdaq: ANIK) today announced that it has entered into a new agreement with Medline Industries, Inc. to commercialize the Company's advanced wound care product - Hyalomatrix(R), in the United States on an exclusive basis through 2019. According to the agreement, Anika will receive product payment and royalty revenues from the sale of the product by Medline. Hyalomatrix(R) is a biologically-derived matrix for in-growing cells, and has the U.S. Food and Drug Administration marketing clearance.
Anika Therapeutics Up 36.4% Since SmarTrend Uptrend Call (ANIK)
Comtex SmarTrend(R) - Mon Jul 28, 5:06PM CDT
SmarTrend identified an Uptrend for Anika Therapeutics (NASDAQ:ANIK) on February 21st, 2014 at $34.67. In approximately 5 months, Anika Therapeutics has returned 36.35% as of today's recent price of $47.28.
Scheduled Conference Calls and Product Launches - Research Reports on Anika Therapeutics, NeoGenomics, HeartWare, Sangamo and Dyax
PR Newswire - Wed Jul 23, 7:40AM CDT
Today, Analysts Review released its research reports regarding Anika Therapeutics, Inc. (NASDAQ: ANIK), NeoGenomics, Inc. (NASDAQ: NEO), HeartWare International Inc (NASDAQ: TWR), Sangamo BioSciences, Inc. (NASDAQ: SGMO) and Dyax Corp (NASDAQ: DYAX). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/5011-100free.
Global Hyaluronic Acid Products (Single-Injection, Three-Injection Cycle and Five-Injection Cycle) Market 2014-2019
M2 - Mon Jul 21, 3:50AM CDT
Research and Markets (http://www.researchandmarkets.com/research/6ct2qw/hyaluronic_acid) has announced the addition of the "Global Hyaluronic Acid Products (Single-Injection, Three-Injection Cycle and Five-Injection Cycle) Market 2014-2019" report to their offering. Hyaluronic acid (HA) is a glycosaminoglycan that helps in transportation of nutrients through the body and facilitate water retention in body tissue. It is naturally found in body - in joints, eye cavity, immune system and others. HA was observed to be an important component of articular cartilage where it is present in the form of a coat around each chondrocyte. This report studies the global hyaluronic acid products market by types of products, applications and the major geographic markets. Products market is segmented as single-injection, three-injection cycle and five-injection cycle. Similarly, applications market is segmented as osteoarthritis, ophthalmic surgery, dermal fillers and vesicoureteral reflux (VUR). The market overview section of the hyaluronic acid products market report discusses the market dynamics with respect to market drivers, restraints and opportunities. This section also covers market attractiveness analysis (by geography) and Porter's five forces analysis for the global hyaluronic acid products market. Market share (%) for the major players operating in this market has also been provided for the year 2012, followed by a list of recommendations for the existing and new players to enter and enhance their market shares. The report concludes with the company profiles of key players operating in various segments of the market. Each company profile includes the business overview, financial overview, product portfolio, business strategies and recent developments of the respective company. Some of the prominent players in the hyaluronic acid products market that have been profiled in this report include Allegran Inc., Anika Therapeutics, Inc., Merz Aesthetics, Inc., Sanofi (Genzyme) and Seikagaku. The global hyaluronic acid products market is segmented as follows: Hyaluronic Acid Products Market, by Products - Single-injection - Three-injection cycle - Five-injection cycle Hyaluronic Acid Products Market, by Applications - Osteoarthritis - Ophthalmic - Dermal Fillers - Vesicoureteral Reflux (VUR) Key Topics Covered: Chapter 1 Introduction Chapter 2 Executive Summary Chapter 3 Market Overview Chapter 4 Global Hyaluronic Acid Products Market, by Products Chapter 5 Global Hyaluronic Acid Products Market, by Applications Chapter 6 Global Hyaluronic Acid Products Market, by Geography Chapter 7 Recommendations Chapter 8 Company Profiles - Alcon, Inc. - Allergan, Inc. - Anika Therapeutics, Inc. - F. Hoffmann-La Roche Ltd. - Ferring Pharmaceuticals, Inc. - Fidia Farmaceutici SpA - GALDERMA S.A. - Hyaltech Ltd. - LifeCore Biomedical LLC, - Meiji Seika Pharma Co., Ltd. - Merz Aesthetics, Inc. - Sanofi - Salix Pharmaceuticals, Inc. - Seikagaku Corporation - Shanghai Jingfeng Pharmaceutical Co., Ltd. - Smith & Nephew plc - TRB CHEMEDICA INTERNATIONAL SA - Zimmer Holdings, Inc. For more information visit http://www.researchandmarkets.com/research/6c...ronic_acid
Anika Therapeutics Announces Date of Second-Quarter 2014 Financial Results Conference Call
Business Wire - Tue Jul 15, 3:05PM CDT
Anika Therapeutics, Inc. (Nasdaq: ANIK) today announced that it plans to issue its second-quarter 2014 financial results after the close of the market on Wednesday, July 30, 2014. The company plans to hold a conference call the next day, Thursday, July 31 at 9:00 a.m. ET to discuss its financial results, business highlights and outlook. In addition, the company will answer questions concerning business and financial developments and trends, and other business and financial matters affecting the company, some of the responses to which may contain information that has not been previously disclosed.
44.4% Return Seen to Date on SmarTrend Anika Therapeutics Call (ANIK)
Comtex SmarTrend(R) - Mon Jul 14, 9:40AM CDT
SmarTrend identified an Uptrend for Anika Therapeutics (NASDAQ:ANIK) on February 21st, 2014 at $34.68. In approximately 5 months, Anika Therapeutics has returned 44.37% as of today's recent price of $50.06.
Biotech Stocks Gilead, Anika Still Near Buy Points
at Investor's Business Daily - Mon Jul 07, 4:39PM CDT
Biotechs Gilead Sciences (GILD) and Anika Therapeutics (ANIK) are among just a few stocks in the Spotlight screen that are still hovering near buy points. Anika, which makes treatments for tissue protection, healing and repair, cleared a 49.47 buy...
Uptrend Call Working As Anika Therapeutics Stock Rises 41.6% (ANIK)
Comtex SmarTrend(R) - Mon Jul 07, 9:20AM CDT
SmarTrend identified an Uptrend for Anika Therapeutics (NASDAQ:ANIK) on February 21st, 2014 at $34.68. In approximately 5 months, Anika Therapeutics has returned 41.60% as of today's recent price of $49.10.
Appointments, Acquisitions, Study Results, and Technical Updates - Analyst Notes on Alere, AMRI, Anika Therapeutics, Nektar and Sangamo
PR Newswire - Fri Jul 04, 5:30AM CDT
Today, Analysts Review released its analysts' notes regarding Alere Inc. (NYSE: ALR), Albany Molecular Research Inc. (NASDAQ: AMRI), Anika Therapeutics Inc. (NASDAQ: ANIK), Nektar Therapeutics (NASDAQ: NKTR) and Sangamo Biosciences Inc. (NASDAQ: SGMO). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/4465-100free.
35.5% Return Seen to Date on SmarTrend Anika Therapeutics Call (ANIK)
Comtex SmarTrend(R) - Fri Jun 27, 9:12AM CDT
SmarTrend identified an Uptrend for Anika Therapeutics (NASDAQ:ANIK) on February 21st, 2014 at $34.68. In approximately 4 months, Anika Therapeutics has returned 35.54% as of today's recent price of $47.00.
Anika Therapeutics Has Returned 31.8% Since SmarTrend Recommendation (ANIK)
Comtex SmarTrend(R) - Thu Jun 19, 4:50PM CDT
SmarTrend identified an Uptrend for Anika Therapeutics (NASDAQ:ANIK) on February 21st, 2014 at $34.68. In approximately 4 months, Anika Therapeutics has returned 31.77% as of today's recent price of $45.69.
Pricing of Offering, FDA Approvals, Launches, and Technical Updates - Analyst Notes on Tenet, Lannett, Wright Medical Group, Anika Therapeutics and Accuray
PR Newswire - Thu Jun 19, 5:00AM CDT
Today, Analysts Review released its analysts' notes regarding Tenet Healthcare Corp. (NYSE: THC), Lannett Company, Inc. (NYSE: LCI), Wright Medical Group Inc. (NASDAQ: WMGI), Anika Therapeutics Inc. (NASDAQ: ANIK) and Accuray Incorporated (NASDAQ: ARAY). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/3879-100free.
